Services
Online Inquiry

For research use only. Not intended for any clinical use.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Non-Human Primate (NHP) Small Molecule Quantitation (LC-MS/MS) Service

Are you currently facing challenges with long drug development cycles, complex preclinical study designs, or the need for precise, reliable data from NHP models? Creative Biolabs' NHP Small Molecule Quantitation service helps you accelerate your drug discovery and development timeline by providing high-quality, actionable data through advanced mass spectrometry techniques. Our platform delivers unparalleled sensitivity, specificity, and throughput, ensuring you can make confident, data-driven decisions at every stage of your project.

Introduction to Our NHP Small Molecule Quantitation Service

Non-human primates (NHPs) are an indispensable model in preclinical research due to their remarkable physiological, genetic, and immunological similarities to humans. These characteristics make them the gold standard for bridging the gap between rodent models and human clinical trials, particularly for novel therapeutics. To understand a drug's safety and efficacy in NHPs, the precise measurement of drug compounds, metabolites, and endogenous biomarkers in biological samples is a critical step. For this, Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) has become the leading analytical technique.

What Our Service Is

Creative Biolabs' NHP Small Molecule Quantitation service utilizes a powerful and selective analytical method to accurately measure low-molecular-weight compounds in samples from NHPs. Our platform is essential for:

  • PK and TK: We provide precise measurement of drug concentrations over time, which is fundamental for understanding how the body absorbs, distributes, metabolizes, and excretes the compound, thereby determining a safe and effective human dose.
  • Biomarker Discovery and Validation: Our services support the identification and quantification of novel biomarkers, such as those indicating a host's response to radiation or infection, providing crucial insights into disease pathogenesis and drug efficacy.
  • Metabolomic Analysis: We can profile a broad range of endogenous metabolites to understand the metabolic state of the NHP and how it is affected by a disease or a drug, offering a holistic view of the biological system.

Why Choose Us?

Many researchers struggle with the logistical hurdles and high costs of developing custom assays or relying on platforms that lack the necessary sensitivity for complex NHP matrices. Creative Biolabs provides a clear path forward by:

  • Minimizing Logistical Hurdles: Unlike antibody-based immunoassays that require specific antibody development for each compound, our LC-MS/MS platform is a universal solution, making method development faster and more cost-effective.
  • Delivering High-Quality Data: The inherent specificity of LC-MS/MS eliminates interference from the complex biological matrix, ensuring that the data you receive is accurate, reproducible, and reliable, giving you confidence in your preclinical findings.
  • Enabling Microsampling: Our high-sensitivity methods allow for analysis from very small sample volumes, reducing the stress on NHPs and aligning with ethical and regulatory guidelines for animal research.

A schematic diagram of the experimental design. (OA Literature)Fig.1 Schematic diagram of LC-MS/MS experiment in NHPs.1

Key Benefits of Our Service

Creative Biolabs' NHP Small Molecule Quantitation service offers distinct advantages that streamline your research and accelerate your time to market. The unparalleled sensitivity and specificity of our LC-MS/MS platform ensure accurate data, even at low concentrations, which is vital for PK/TK studies. The ability to multiplex—quantifying multiple compounds in a single run—maximizes efficiency and conserves valuable NHP samples.

  • Unrivaled Response Speed: Our streamlined workflow and dedicated scientific teams allow us to provide rapid turnaround times, ensuring you get critical data when you need it most.
  • Extensive NHP Resources: We have established procedures and extensive experience working with a wide range of NHP species, including marmosets, rhesus macaques, and others, ensuring a seamless experience regardless of your model.
  • Superior Customization: Our expert scientists work closely with your team to develop and validate methods tailored to your specific compound and biological matrix, ensuring the assay meets your unique project goals.
  • In-depth Reporting: You will receive comprehensive reports that go beyond raw numbers, including detailed analysis and expert interpretation to help you fully understand the implications of your data.

How Creative Biolabs' NHP Services Can Assist Your Project?

Creative Biolabs' NHP PK/TK Sample Analysis Services provide a seamless, end-to-end solution for your non-clinical development needs. We handle every step with meticulous care, from initial project design to final data delivery, ensuring you have the precise information required to move your project to the next stage.

01

Required Starting Materials

02

Method Development & Optimization

03

Method Validation

04

Bioanalytical Method Validation

05

Sample Analysis

06

Data Processing & Reporting

Key Deliverables

  • Comprehensive Project Report
  • Raw LC-MS/MS Data Files
  • Method Development and Validation Summary
  • Study Summary and Key Findings

Capabilities & Partnerships

Service-Specific Data

  • Annual Sample Size: Over 50,000 samples analyzed per year.
  • Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
  • Study Pass Rate: 99%+ success rate in meeting study endpoints.

Our Valued Partners

Frequently Asked Questions

Q: Can your LC-MS/MS service handle a wide range of NHP biological matrices?
A: Absolutely. Our platform is highly versatile and our scientists have extensive experience working with a variety of matrices, including plasma, serum, urine, and cerebrospinal fluid. We carefully optimize our sample preparation methods to minimize matrix effects, ensuring you get accurate and reliable data regardless of the sample type.
Q: How do your services compare to traditional immunoassay methods for small molecule quantitation?
A: While immunoassays have their place, LC-MS/MS offers significant advantages, particularly for small molecules. Our methods do not require the time-consuming development of specific antibodies, which makes our process faster and more flexible. Additionally, the high specificity of LC-MS/MS reduces the risk of interference from anti-drug antibodies that can plague immunoassay results.
Q: What if our project involves a novel compound or one with a very low concentration?
A: This is where our expertise truly shines. Our scientists are specialists in developing highly sensitive and selective methods for challenging compounds. We can perform custom method development and validation to ensure that even low-concentration molecules are accurately and reliably quantified.
Q: What is the benefit of using LC-MS/MS for biomarker discovery in NHPs?
A: LC-MS/MS is a powerful tool for biomarker discovery because it can analyze a broad range of metabolites and proteins in a single run. This enables us to identify comprehensive metabolic signatures, such as those indicating a host's response to infection or radiation, giving you a holistic view of the biological system.
Q: How do we get started with your NHP Small Molecule Quantitation service?
A: It's a very straightforward process. The best first step is to contact our team to discuss your project. We'll work with you to understand your specific needs and provide a customized plan and quote to get your research moving forward.

Contact Us

Creative Biolabs is your trusted partner for NHP Small Molecule Quantitation (LC-MS/MS). Our robust platform, coupled with our deep scientific expertise, provides a powerful solution to the complexities of preclinical research. We are committed to delivering the high-quality, actionable data you need to drive your drug development programs forward with confidence. Contact our team for more information and to discuss your project.

Reference

  1. Chiang, Chih-Yuan, et al. "Proteomic Analysis of Non-human Primate Peripheral Blood Mononuclear Cells During Burkholderia mallei Infection Reveals a Role of Ezrin in Glanders Pathogenesis." Frontiers in microbiology 12 (2021): 625211, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2021.625211
Cart
Cart